Find us on:

Research

Low Dose Naltrexone and Lung Cancer: A Case Report and Discussion

Title
Low Dose Naltrexone and Lung Cancer: A Case Report and Discussion
Publication Type
Journal Article
Research Type
Human
Reported as
Case Report/Series/Restrospective Study
Date
July 05, 2018
Authors
J.A. Miskoff, M. Chaudhri
Institution
Jersey Shore University Medical Center
Link
Abstract

Low dose naltrexone (LDN) has been promising as a complementary medication for patients with a broad range of medical disorders. Although not a proven cure, evidence from clinical trials supports LDN as being a valuable adjunct for disorders in which the immune system plays a centralized role. Additionally, clinical trials have proposed a unique mechanism(s) allowing LDN to affect tumors including non-small cell lung cancer (NSCLC) at the cellular level by augmenting the immune system. We present a case of a 50-year-old male with a prolonged survival and a past medical history of prostate and lung cancer.